Species-differences in disposition and reductive metabolism of methoxymorpholinodoxorubicin (PNU 152243), A new potential anticancer agent

Pharmacological Research

Volumn 41, Issue 2, 2000, Pages 239-248

  Breda, M ^a,b   Benedetti, M Strolin ^a,b   Battaglia, R ^a,b   Castelli, M G ^a,b   Poggesi, I ^a,b   Spinelli, R ^a,b   Hackett, A M ^a,b   Dostert, P ^a,b  

^a PFIZER INC   (United States)

^b Lab Drug Metab   (Italy)

Author keywords

Aldo keto reductase activity; Anthracyclines; Metabolism; Methoxymorpholinodoxorubicin; Species differences

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG METABOLITE; NEMORUBICIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE; URINARY EXCRETION;

EID: 0033844217     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1999.0584     Document Type: Article

References (25)

1. Novel anthracycline analogues
2. 3'-deamino-3'-[2(S)-methoxy-4-morpholinyl) doxorubicin (FCE 23762): A new anthracycline derivative with enhanced cytotoxicity and reduced cardiotoxicity
3. The cellular and biochemical pharmacology of the methoxymorpholino derivative of doxorubicin
4. Mechanistic studies with methoxymorpholino-doxorubicin: Evidence of a novel covalently bound DNA adduct following activation by Cyt P450 3A
5. Cytoplasmic aldo-keto reductases: A class of drug metabolizing enzymes
6. Comparative mammalian metabolism of adriamycin and daunorubicin
7. Anthracycline antibiotic pharmacology and metabolism
8. 14C-labelled 4'-epidoxorubicin and doxorubicin in the rat. A comparative study
9. Pharmacokinetics of anthracyclines in dogs: Evidence for structure-related body distribution and reduction to their hydroxy metabolites
10. Chemioterapici antitumorali
11. 14C]4-daunorubicin HCl in the rat
12. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans
13. Lipophilic character and biological activity of anthracyclines
14. Pharmacology and clinical toxicity of 4'-deoxy-4'-iododoxorubicin: An example of successful application in pharmacokinetics to dose escalation in phase I trials
15. Pharmacokinetics of iododoxorubicin in the rat, dog and monkey
16. Stereoselectivity of iodo-doxorubicin reduction in various animal species and humans
17. Absorption, disposition and urinary metabolism of FCE 23762, a new doxorubicin derivative in the rat
18. 14C-labelled 3'-deamino-3'-[2(S)-methoxy-4-morpholinyl]doxorubicin.HCl, a new antitumoral morpholinyl anthracycline
19. Determination of 3'-deamino-3'-[2(S)-methoxy-4-morpholinyl] doxorubicin, a new morpholinyl anthracycline, in plasma by high-performance liquid chromatography with fluorescence detection
20. Stretching HPLC sensitivity to measure subnanogram levels of FCE 23762, a novel anthracycline and its 13-dihydro metabolite in human plasma
21. Testing for the equality of the area under the curves when using destructive measurement techniques
22. Stereoselectivity of idarubicin reduction in various animal species and humans
23. In vitro reduction of iododoxorubicin and doxomorpholin by aldo-keto reducatse(s) in rat and human whole blood
24. Phase I clinical and pharmacokinetic study of methoxymorpholinyl-doxorubicin (FCE 23762)